A human clonal glioma cell line, U-343 MGa Cl 2, cultured under serum-free conditions, was found to release a factor that competed with 2.51-labeled platelet-derived growth factor (1251-PDGF) for binding to human foreskin fi-
broblasts. The concentration of competing activity in conditioned medium was equal to 20-30 ng of PDGF per ml. The PDGF receptor competing activity had an elution position on Sephadex G-200 close to that of tracer PDGF. The same fractions in the chromatogram also contained growth-promoting activity and material active in a PDGF radioimmunoassay. Incubation of partially purified, 125I-labeled glioma factor with fibroblasts, or a rabbit anti-PDGF serum, led to the selective binding of a component with an estimated Mr of 31,000, as shown by NaDodSO4/gel electrophoresis under nonreducing conditions. After reduction this component migrated as a Mr 18,000 protein. Thus, the behavior in NaDodSO4/gel electrophoresis was similar to that of PDGF. Furthermore, incubation of partially purified glioma factor with immobilized PDGF antibodies markedly decreased the amount of PDGF receptor competing activity remaining in the supernatant. These results suggest that the factor produced by glioma cells has structural, immunological, and functional resemblance to PDGF. We previously reported that a human osteosarcoma cell line produces a PDGF-like molecule with growth-promoting activity. Taken together with the recent finding that PDGF is homologous to the transforming gene product of simian sarcoma virus, our present data give additional support for the idea that an autocrine activation of the PDGF receptor may be operational in the growth of human tumors of mesenchymal or glial origin.
Platelet-derived growth factor (PDGF), a cationic protein of Mr 30,000, is a potent growth factor for connective tissuederived cells and glial cells in culture (1) (2) (3) . In vivo, PDGF is probably synthesized in the megakaryocyte, stored in the platelet a-granules, and released by the platelet-release reaction (4-6). Consequently, under normal conditions cells may not be exposed to PDGF; only when platelets degranulate does PDGF become free to diffuse into tissue. The storage form of PDGF in conjunction with its restricted cell specificity implies a physiological role of PDGF in the stimulation of cell regeneration in response to tissue damage.
A partial amino acid sequence of human PDGF has recently been determined (7) (8) (9) . The obtained sequence shows virtual identity with that of p28Sis, the putative transforming protein of simian sarcoma virus (10) . This finding suggests that neoplastic transformation involves the expression of growth factors, which may be encoded by oncogenes. Recent studies have clearly shown that certain tumor cells do release growth factors. One example is the finding of transforming growth factors (TGFs) produced by virus-transformed cells (11) (12) (13) . TGF not only stimulates cell proliferation but also, in certain systems, is capable of inducing anchorage-independent growth. Because TGF blocks the binding of epidermal growth factor (EGF) (11) , some of its cellular effects are probably mediated by the EGF receptor; however, recent data derived from cross-linking studies indicate that TGF also binds to a cell receptor, distinct from the EGF receptor (14) . Furthermore, growth factors related to PDGF have been isolated from human osteosarcoma cells (15) and from simian virus 40 (SV40)-transformed baby hamster kidney (BHK) cells (16, 17) .
Recent improvements in PDGF radioligand techniques (18) (19) (20) (21) (22) , have enabled us to investigate whether PDGF or PDGF-like factors are produced by human tumor cells. We now report on a human clonal glioma cell line (U-343 MGa Cl 2) that releases a Mr 31,000 growth factor with structural and immunological characteristics in common with PDGF. §
MATERIALS AND METHODS
Cell Culture. The in vitro characteristics of the human clonal glioma cell line U-343 MGa Cl 2 have been described (24) . Human foreskin fibroblasts (line AG 1523) were purchased from the Human Mutant Cell Repository, Institute for Medical Research (Camden, NJ). Cells were routinely grown in 10-cm Petri dishes (Nunc) in Eagle's minimum essential medium, supplemented with 10% newborn calf serum (GIBCO) and antibiotics (100 units of penicillin and 50 ,ug of streptomycin per ml). Cultures were maintained at 37°C in humidified air containing 5% CO2. Cultures were subcultivated once or twice a week at 1:2 split ratio using 0.2 mg of EDTA per ml and 2.5 mg of trypsin (Difco) per ml in phosphate-buffered saline as detaching agents.
For the harvest of larger amounts of serum-free conditioned media from U-343 MGa Cl 2 cultures, cells were transferred to Falcon plastic roller bottles (850 cm2) at 1:5 split ratio (cm2/cm2) using 100 ml of Eagle's medium, supplemented with 10% newborn calf serum, antibiotics, and 10 mM Hepes (pH 7.4) per bottle. Roller bottles were incubated at 37°C and rotated at 0.5 rpm in a Bellco Technorama apparatus. Medium was changed twice a week. When the cells had grown to confluence, the rollers were washed three times with phosphate-buffered saline and incubated with 100 ml of serum-free F-10 medium per bottle. Medium was harvested twice a week as long as the cells appeared viable (1-2 months). Detached cells and debris were removed by centrifugation (10,000 x g for 10 min) and conditioned media were stored in plastic bottles at -20°C until processed further. For Abbreviations: PDGF, platelet-derived growth factor; 125I-PDGF, "251-labeled PDGF; TGF, transforming growth factor; EGF, epidermal growth factor. tTo whom reprint requests should be addressed.
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small-scale experiments, serum-free media were harvested in an analogous way from cells grown in 10-cm Petri dishes. PDGF. Pure PDGF was prepared as described (25) and radiolabeled using the chloramine-T method to a specific activity of -20,000 cpm/ng (18) .
Assay for PDGF Receptor Competing Activity. PDGF receptor competing activity was measured on human foreskin fibroblasts. Cells were seeded in 12-well plates, grown to confluence, and washed once with binding buffer (phosphate-buffered saline containing 1 mg of human serum albumin per ml/0.01 mg of CaCl2-2H2O per ml/0.01 mg of MgSO4-7H2O per ml). Test samples (40C), diluted in binding buffer, were then added and the plates were incubated at 40C for 2 hr. Cells were washed 3 times with binding buffer. Each well then received 0.5 ml of binding buffer containing 5 ng (100,000 cpm) of 1251-labeled PDGF (125I-PDGF). After incubation for 1 hr at 40C, cultures were washed 6 times with binding buffer containing 1% newborn calf serum instead of albumin. Cell-associated radioactivity was extracted with 0.5 ml of lysis buffer (1% Triton X-100/20 mM Hepes, pH 7.4/10% (vol/vol) glycerol, supplemented with 0.1 mg of bovine serum albumin per ml). The Triton lysate was sampled after 20 min and the radioactivity was determined in a gamma spectrometer. Nonspecific binding was determined as the amount of 125I-PDGF bound in the presence of a 50-fold molar excess of unlabeled partially purified PDGF. PDGF receptor competing activity of samples was converted to equivalent ng/ml of PDGF, using a standard curve constructed from results obtained with pure unlabeled PDGF (5-100 ng per ml).
PDGF Radioimmunoassay. Antibodies against pure PDGF were raised in a rabbit as described (19) . The immunoglobulin fraction, purified using Staphylococcus protein A Sepharose, was used to establish a radioimmunoassay against PDGF. Briefly, 96-well Multiwell Disposo-Trays (Linbro)
were coated with anti-PDGF immunoglobulins (100 Al per well, 0.25 mg per ml in phosphate-buffered saline) for 30 min at room temperature. After washing 3 times in phosphatebuffered saline, test samples (100 ,ul), diluted in washing buffer (0.5 M NaCl/0.01 M phosphate buffer, pH 7.4/0.5% bovine serum albumin/0.1% Tween 80) were added. The plates were then incubated for 16 hr at 4°C under continuous shaking. At this time, test samples were removed and the wells received 100 ,ul of 1251-PDGF (20,000 cpm) in washing buffer and incubation was prolonged for another 2 hr. After washing 3 times with washing buffer, immobilized radioactivity was released by incubation with 0.3 M NaOH (100 1I per well) for 10 min at room temperature. The assay was calibrated with pure PDGF (0.5-50 ng).
Assay for Growth-Promoting Activity. Growth-promoting activity was determined using a method of [3Hlthymidine incorporation in serum-free cultures of human foreskin fibroblasts (line AG 1523). Cells were plated in Eagle's minimal essential medium/10% newborn calf serum, at a split ratio of 1:10, in Nunc 35-mm dishes. After 4 days of incubation, medium was removed and the cultures were incubated for 2 days in serum-free MCDB 105 medium with a decreased concentration of Ca2+ (0.5 mM). Test samples were then added along with [3H]thymidine (specific activity, 5 Ci/ mmol, 1 Ci = 37 GBq; final concentration, 0.02 ,Ci/ml). After 2 days of incubation, cultures were extracted with 10% trichloroacetic acid, washed in running tap water, and lysed with 0.3 M NaOH/1% NaDodSO4 in water. Radioactivity was determined in a liquid scintillation counter. The activity of test samples was compared to that obtained with various concentrations of pure PDGF (0.5-10 ng per ml).
Partial Purification of the PDGF Analog Released by a Human Glioma Cell Line. Six liters of serum-free conditioned medium from U-343 MGa Cl 2 cultures were harvested as described above. The active component was then concentrated by adsorption to Sulphadex beads (sulphated Sephadex G-50 medium; ref. 26); the conditioned medium was incubated with 120 ml of Sulphadex beads overnight at 40C under continuous shaking. The gel was then collected by sedimentation and poured into a column. After washing with 50 ml of phosphate-buffered saline, the column was eluted with 300 ml of 2 M NaCI/0.01 M phosphate buffer, pH 7.4. Solid ammonium sulfate was then added to the eluate to 70% saturation, and the precipitate was collected by centrifugation at 10,000 x g for 30 min. It was then dissolved in 1.5 ml of 1 M NaCl/0.01 M phosphate buffer, pH 7.4, and applied to a Sephadex G-200 column (1 x 145 cm) equilibrated with the same buffer. The column was eluted at a flow rate of 4 ml per hr and effluent fractions were analyzed for protein, growthpromoting activity, and for radioreceptoractive and radioimmunoactive PDGF.
Cell Binding of Radiolabeled Partially Purified Material. Ten micrograms of protein derived from the peak fractions of the Sephadex G-200 chromatogram (75-87 ml eluted volume) was radiolabeled with 1251 according to the procedure used for the radiolabeling of PDGF (18) . 1251-labeled partially purified material (1.5 x 106 cpm) or 125I-PDGF (105 cpm) was exposed to human foreskin fibroblasts (AG 1523) in 0.5 ml of binding medium for 2 hr at 40C in the presence or absence of unlabeled PDGF (1 ,ug/ml). After washing 5 times with binding medium, cells were removed from the culture dishes with a rubber policeman and collected by centrifugation at 10,000 x g for 1 min. The cell pellets were then extracted with 80 ,ul of 1% Triton X-100/10% glycerol/20 mM Hepes, pH 7.4. After 15 min at 4°C, samples were centrifuged at 10,000 x g for 2 min, and the supernatant was incubated with 80 ,ul of 3.6% NaDodSO4/80 mM Tris HCl, pH 8.8/0.01% bromophenol blue for 3 min at 95°C. Samples were then divided into two equal parts, one of which was reduced with 10 mM dithiothreitol before NaDodSO4/gel electrophoresis.
Immunoprecipitation of Radiolabeled Partially Purified Material. Radiolabeled partially purified material (3 x 106 cpm) or 125I-PDGF (105 cpm) was incubated with 10 ,ul of anti-PDGF immune serum, or a nonimmune serum, in a total volume of 30 ,lA for 4 hr at 4°C. Protein A Sepharose (Pharmacia) (20 ,ul of packed beads in a volume of 40 ,ul) was then added, and incubation was prolonged for another 30 min at 4°C. After washing 4 times in radioimmunoassay washing buffer (see above) and 1 time in 10 mM phosphate buffer (pH 7.4), protein A Sepharose-bound radioactivity was released by incubation for 3 min at 95°C in 3.6% NaDodSO4/80 mM Tris-HCl, pH 8.8/0.01% bromophenol blue. The samples were then divided in two equal parts, one of which was reduced with 10 mM dithiothreitol before NaDodSO4/gel electrophoresis.
Polyacrylamide Gel Electrophoresis in NaDodSO4. Gel electrophoresis in NaDodSO4 was carried out as described (27) , using 13-18% acrylamide gradient gels. Gel dimensions were 300 x 200 x 1 mm and gels were run overnight at a constant current at room temperature. After electrophoresis, gels were stained for protein, dried, and subjected to autoradiography (28) . RESULTS PDGF Receptor Competing Activity in Glioma Conditioned Medium. Serum-free conditioned medium was harvested from confluent cultures of U-343 MGa Cl 2 cells after 3 days of incubation and analyzed with regard to competition with 125I-PDGF for binding to the PDGF receptor (Fig. 1) . A dose-dependent PDGF receptor competing activity was found; its concentration in the harvested medium was equivalent to 20-30 ng of PDGF per ml. The cumulative production of competing activity was essentially linear with time over a period of 18 days and virtually parallel to the accumulation of protein in the extracellular medium (Fig. 2 ).
Medical Sciences: Nistdr et al. (Fig. 4) . Binding of this component did not occur in the presence of excess unlabeled PDGF, indicating that it involved the PDGF receptor in a specific manner. After reduction, the bound component appeared as a single band with a higher electrophoretic mobility, indicating a Mr of 18,000. It was concluded that the 125I-labeled preparation of glioma factor contained a PDGFlike component having similar receptor-binding and molecular weight properties as authentic PDGF.
Recognition by PDGF Antibodies. (Fig. 5) . Under reducing conditions it attained the mobility of a Mr 18,000 component. In conclusion, a PDGF-like species was among the 125I-labeled glioma products; it was specifically recognized by PDGF antibodies and had similar electrophoretic characteristics as PDGF proper. An analogous experiment was carried out with unlabeled glioma factor to examine whether PDGF-antibodies similarly recognized PDGF receptor competing activity. A preparation of glioma factor that had been passed over a Sulphadex column was incubated overnight with Sepharose 4B beads to which PDGF antibodies had been coupled. This treatment markedly decreased the amount of PDGF receptor competing activity remaining in the supernatant (Table 1) . A similar effect was noticed in experiments with pure PDGF Tather than glioma factor, whereas, in contrast, plain Sepharose beads did not decrease PDGF receptor-competing activity in either case.
DISCUSSION
The present data show that serum-free conditioned medium from the human clonal glioma cell line U-343 MGa Cl 2 blocks the binding of 1214-PDGF to human foreskin fibroblasts. Several lines of evidence show that this activity is exerted via the binding of a PDGF-like factor to the cellular PDGF receptor. Most compelling evidence was derived from experiments using 125I-labeled partially purified material; both fibroblasts, through their PDGF receptor, and PDGF antibodies selectively recognized a Mr 31,000 component which upon reduction migrated as a Mr 18,000 species on NaDodSO4/gel electrophoresis. According to the model recently proposed (25) , PDGF purified from human platelets consists of two polypeptide chains, designated A and B, which are linked by disulfide bonds. Isolated A chain appears as multiple bands on NaDodSO4/gel electrophoresis in the molecular weight range 18,000-11,000, whereas the B chain migrates as a single Mr 16,000 species. The heterogeneity in molecular weight of unreduced PDGF (25) is thus most probably due to a partial degradation of the A chain, possibly due to a proteolytic cleavage during the course of preparation. lodination of PDGF by the chloramine-T method causes the preferential labeling of the A chain (unpublished observation). Consequently, when 125I-PDGF is electrophoresed under reducing conditions, the B chain does not appear on the autoradiograms. The molecular weight of the glioma-derived factor of the present investigation seems to correspond to a large (Mr 31,000) form of PDGF. Moreover, the 12 I-labeled component recognized by cells and PDGF antibodies behaves after reduction as expected from a PDGF of this molecular weight-i.e., it migrates as a single Mr 18 ,000 species corresponding to a nondegraded A chain.
An immunological crossreactivity of the glioma-derived analog with PDGF was shown by three experimental procedures using PDGF antiserum: immunoprecipitation of 125[_ labeled material as discussed above, absorption of PDGF reMedical Sciences: Niste'r et aL Mrl ceptor binding activity by immobilized PDGF antibodies, and activity in the PDGF radioimmunoassay. Although the glioma-derived factor thus is immunologically related to PDGF,' the two factors do not seem to be identical because the crossreactivity in the radioimmunoassay-did not match the 125I-PDGF competing activity in the receptor binding assay. However, when an excess of PDGF antibodies was used, a major part of the competing activity of the glioma factor was precipitated ( Table 1) . The possibility that a minor part of the glioma factor activity is identical to PDGF and a major part unrelated is thus unlikely.' Rather, these observations support the possibility that the PDGF antibodies recognize all glioma cell produced activity, but at a lower affinity. More detailed information is required, however, to determine if the glioma-derived analog is a different gene product than PDGF or represents a Oost-translationally modified factor. It is noteworthy that TGF produced by virus transformed cells is functionally related to EGF in the sense that it displaced EGF from the EGF receptor but seemingly is immunologically unrelated (11) .
The fact that the growth-promnoting activity of the glioma factor preparation comigrated with authentic PDGF on Sephadex G-200' chromatography supports the idea that this activity should similarly be ascribed to a PDGF-like molecule. Although this has not been rigorously proven, it is reasonable considering the presence of PDGF-receptor binding material in the same fractions. The glioma-derived growth factor is thus another example of a tumor cell-derived analog to PDGF; previously, PDGF-like properties have been assigned to an osteosarcoma-derived growth factor first described by our group (15) and recently confirmed by Graves et al. (29) .
The current interest in tumor-derived growth factors relates to the idea that tumor cells may use endogenous growth factors in an autocrine mahner-i.e., to stimulate'the proliferation of the producer cell itself. In addition, some of these factors interestingly have transforming activity (TGFs)-i.e., ability to cause a reversible phenotypical transformation of normal cells (11) (12) (13) . The recently described amino acid homology between the putative transforming protein of simian sarcoma virus, p28SS, and PDGF suggests that PDGF may be encoded by the normal cellular homologue to v-sis (c-sis). The structural, immunological and functional -similarity between the osteosarcoma (15) and glioma-derived growth factors and PDGF therefore suggests that these tumor-derived factors are also derived from the sis gene family. Interestingly, PDGF seems to act as a transforming growth factor, because it causes an irregular (criss-cross) growth pattern in BALB/c 3T3 cultures (3) and growth in agar of untransformed BHK cells (30) . In addition, both PDGF and the glioma factor induce anchorage-independent growth of nontransformed Rat 1 cells (unpublished observations). Assuming that the PDGF analog of osteosarcoma and glioma cells may also be manufactured in vivo, one may speculate that the autocrine activation of the PDGF receptor may be operational in the growth of these human neoplasms.
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